Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.59 |
| ▸ | RORC | P51449 | 2/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19088665 | 0.96 | HRH3 (0.64) | HRH3RORCCYP2A6LOXL2TSHR | |
| SCHEMBL2201240 | 0.93 | RORC (0.53) | HRH3RORCCYP2A6TSHRHSD17B10 | |
| SCHEMBL2201741 | 0.86 | RORC (0.48) | HRH3RORCCYP2A6TSHRHSD17B10 | |
| SCHEMBL541669 | 0.86 | HRH3 (0.59) | HRH3RORCCYP2A6LOXL2 | |
| SCHEMBL4664138 | 0.85 | HRH3 (0.55) | HRH3RORCCYP2A6LOXL2TSHR | |
| SCHEMBL10990552 | 0.84 | TSHR (0.57) | HRH3RORCCYP2A6TSHRHSD17B10 | |
| SCHEMBL2200787 | 0.83 | MAOA (0.49) | RORC | |
| SCHEMBL2204043 | 0.83 | RORC (0.49) | HRH3RORCCYP2A6 | |
| SCHEMBL29664740 | 0.82 | LOXL2 (0.55) | HRH3RORCCYP2A6LOXL2NSD2 | |
| SCHEMBL1637428 | 0.81 | SIGMAR1 (0.48) | HRH3RORCCYP2A6TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115122-B2 | Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK) | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140179743-A1 | NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179743-A1 | NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) | MAPK1, MAP3K1, MAP3K20 | HRH3 1287/4885RORC 3747/4885CYP2A6 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.